

RECEIVED  
SECRETARY OF THE SENATE  
PUBLIC RECORDS

Clear all o

FIN

06 APR -5 PM 2:10

2/10/06

Clerk of the House of Representatives Legislative Resource Center B-106 Cannon Building Washington, DC 20515	Secretary of the Senate Office of Public Records 232 Hart Building Washington, DC 20510
---	--

### LOBBYING REPORT

Lobbying Disclosure Act of 1995 (Section 5) - All Filers Are Required to Complete This Page

1. Registrant name  
**Abbott Laboratories**

---

2. Address  Check if different than previously reported  
**1399 New York Avenue, NW Suite 200**  
**Washington DC 20005 US**

---

3. Principal place of business (if different than line 2)  
**Abbott Park IL 60064 U**  
City State/Zip or Country

---

4a. Contact Name <b>Mr. Timothy M. Shannon</b>	b. Telephone number <b>202-378-2025</b>	c. E-mail <b>timothy.shannon@abbott.com</b>	5. Senate ID # <b>66-12</b>
7. Client Name <input checked="" type="checkbox"/> Self <b>Abbott Laboratories</b>			6. House ID # <b>300010</b>

TYPE OF REPORT 8. Year 2005 Midyear (January 1-June 30)  OR Year End (July 1-December)

9. Check if this filing amends a previously filed version of this report

10. Check if this is a Termination Report  ⇒ Termination Date \_\_\_\_\_

11. No Lobbying Act

#### INCOME OR EXPENSES - Complete Either Line 12 OR Line 13

<p><b>12. Lobbying Firms</b></p> <p>INCOME relating to lobbying activities for this reporting period was:</p> <p>Less than \$10,000 <input type="checkbox"/></p> <p>\$10,000 or more <input type="checkbox"/> ⇒ \$ _____</p> <p>Provide a good faith estimate, rounded to the nearest \$20,000, of all lobbying related income from the client (including all payments to the registrant by any other entity for lobbying activities on behalf of the client).</p>	<p><b>13. Organizations</b></p> <p>EXPENSES relating to lobbying activities for this reporting period were:</p> <p>Less than \$10,000 <input type="checkbox"/></p> <p>\$10,000 or more <input checked="" type="checkbox"/> ⇒ \$ <u>1,760,000</u></p> <p><b>14. REPORTING METHOD.</b> Check box to indicate exp accounting method. See instructions for description of opt</p> <p><input checked="" type="checkbox"/> <b>Method A.</b> Reporting amounts using LDA definitions.</p> <p><input type="checkbox"/> <b>Method B.</b> Reporting amounts under section 6033(b)(1) Internal Revenue Code</p> <p><input type="checkbox"/> <b>Method C.</b> Reporting amounts under section 162(e) of Revenue Code</p>
--	--

0000142399

Signature \_\_\_\_\_ Date \_\_\_\_\_



Printed Name and Title Timothy M. Shannon - Director, Government Affairs Operations

LD-2DS (Rev. 4.06)

Page 1

Registrant Name Abbott Laboratories Client Name Abbott Laboratories

**LOBBYING ACTIVITY.** Select as many codes as necessary to reflect the general issue areas in which the engaged in lobbying on behalf of the client during the reporting period. Using a separate page for each code information as requested. Attach additional page(s) as needed.

15. General issue area code AGR - Agriculture (one per page)

16. Specific lobbying issues

Implementation of Public Law 108-265, Child Nutrition Improvement and Integrity Act.

17. House(s) of Congress and Federal agencies contacted  Check if None

Department of Agriculture  
House of Representatives  
Senate

18. Name of each individual who acted as a lobbyist in this issue area

Name			Covered Official Position (if applicable)
Rosemary T.	Haas	Ms.	
Elaine R.	Leavenworth	Ms.	
Howard D.	Scholick	Mr.	
John M.	Taylor	Mr.	Associate Commissioner, FDA

19. Interest of each foreign entity in the specific issues listed on line 16 above  Check if None

Signature \_\_\_\_\_ Date \_\_\_\_\_

1000142400

10

Printed Name and Title Timothy M. Shannon - Director, Government Affairs Operations

LD-2DS (Rev. 4.06)

Page \_

Registrant Name Abbott Laboratories Client Name Abbott Laboratories

**LOBBYING ACTIVITY.** Select as many codes as necessary to reflect the general issue areas in which the engaged in lobbying on behalf of the client during the reporting period. Using a separate page for each code information as requested. Attach additional page(s) as needed.

15. General issue area code BUD - Budget/Appropriations (one per page)

16. Specific lobbying issues

Implementation of Public Law 108-199, Consolidated Appropriations Act, 2004 - relating to HIV/AIDS procurement policy.

H.R.2744, Agriculture, Rural Development, Food and Drug Administration, and Related Agencies Appropriations Act, 2006 - relating to Special Supplemental Feeding Program for Women, Infants, and Children, and drug importation.

17. House(s) of Congress and Federal agencies contacted  Check if None

Department of Agriculture  
Department of Health & Human Services  
House of Representatives  
Senate

18. Name of each individual who acted as a lobbyist in this issue area

Name			Covered Official Position (if applicable)
P. Claude	Burcky	Mr.	
Rosemary T.	Haas	Ms.	
Elaine R.	Leavenworth	Ms.	
Jennifer M.	Luray	Ms.	
Howard D.	Scholick	Mr.	
Cynthia B.	Sensibaugh	Ms.	
John M.	Taylor	Mr.	Associate Commissioner, FDA
James J.	White	Mr.	

19. Interest of each foreign entity in the specific issues listed on line 16 above  Check if None

0000142401



Printed Name and Title Timothy M. Shannon - Director, Government Affairs Operations

LD-2DS (Rev. 4.06)

Go to

Registrant Name Abbott Laboratories Client Name Abbott Laboratories

**ADDENDUM for General Lobbying Issue Area BUD**

16. Specific lobbying issues (continued from previous page)

H.R.3010, Departments of Labor, Health and Human Services, and Education, and Related Agencies Appropriations Act, 2006 - funding for State AIDS Drug Assistance Program under the Ryan White Act, aut generics amendment, and chronic kidney disease awareness.

S.1932, Deficit Reduction Omnibus Reconciliation Act of 2005 - relating to Part B drug reimbursement, Mer Reform, and physician fee schedule.

S.1043, DOD Authorization Act, 2006 - relating to dietary supplements.

H.R.2862, Science, State, Justice, Commerce, and Related Agencies Appropriations Act - relating to Intelle property.

H.R. 2528, Military Quality of Life and Veteran Affairs Appropriations Act, 2006 - amendment relating to VA procurement of blood glucose monitors.

0000142402





Registrant Name Abbott Laboratories Client Name Abbott Laboratories

**LOBBYING ACTIVITY.** Select as many codes as necessary to reflect the general issue areas in which the engaged in lobbying on behalf of the client during the reporting period. Using a separate page for each code information as requested. Attach additional page(s) as needed.

15. General issue area code CSP - Consumer Issues/Safety/Protection (one per page)

16. Specific lobbying issues

S.930, Food and Drug Administration Safety Act of 2005 - relating to drug safety.

17. House(s) of Congress and Federal agencies contacted  Check if None

House of Representatives  
Senate

18. Name of each individual who acted as a lobbyist in this issue area

Name			Covered Official Position (if applicable)
Elaine R.	Leavenworth	Ms.	
John M.	Taylor	Mr.	Associate Commissioner, FDA
James J.	White	Mr.	

19. Interest of each foreign entity in the specific issues listed on line 16 above  Check if None

0000142403



Printed Name and Title Timothy M. Shannon - Director, Government Affairs Operations

LD-2DS (Rev. 4.06)

Page 5

Registrant Name Abbott Laboratories Client Name Abbott Laboratories

**LOBBYING ACTIVITY.** Select as many codes as necessary to reflect the general issue areas in which the engaged in lobbying on behalf of the client during the reporting period. Using a separate page for each code information as requested. Attach additional page(s) as needed.

15. General issue area code HCR - Health Issues (one per page)

16. Specific lobbying issues

S.1128, Pharmaceutical Advertising and Prudent Purchasing Act - relating to advertising.  
 H.R. 1626, Medicare Prescription Drug Improvement Act - relating to the importation of prescription drugs and non-interference.

17. House(s) of Congress and Federal agencies contacted  Check if None

Department of Health & Human Services  
 House of Representatives  
 Senate

18. Name of each individual who acted as a lobbyist in this issue area

Name			Covered Official Position (if applicable)
Rosemary T.	Haas	Ms.	
Elaine R.	Leavenworth	Ms.	
Jennifer M.	Luray	Ms.	
Howard D.	Scholick	Mr.	
Cynthia B.	Sensibaugh	Ms.	
John M.	Taylor	Mr.	Associate Commissioner, FDA
James J.	White	Mr.	
Adele R.	Witenstein	Ms.	

19. Interest of each foreign entity in the specific issues listed on line 16 above  Check if None

000142404

00

Printed Name and Title Timothy M. Shannon - Director, Government Affairs Operations

LD-2DS (Rev. 4.06)

Page 1

Registrant Name Abbott Laboratories Client Name Abbott Laboratories

**ADDENDUM for General Lobbying Issue Area HCR**

16. Specific lobbying issues (continued from previous page)

- H.R.328, Pharmaceutical Market Access Act of 2005 - relating to the importation of prescription drugs.
- S.16, S.109, Affordable Health Care Act - relating to the importation of prescription drugs.
- S.184, H.R.753, Safe IMPORT Act of 2005 - Safe Importation of Medical Products and Other Rx Therapies 2005 - relating to the importation of prescription drugs.
- S.334, H.R.700, Pharmaceutical Market Access and Drug Safety Act of 2005 - relating to the importation of prescription drugs.
- S.1074, HELP America Act of 2005 - relating to pediatric nutrition.
- HHS policy and regulations.

0000142405



LD-2DS

Add page to continue specific issues description for thi

Page 7

Registrant Name Abbott Laboratories Client Name Abbott Laboratories

**LOBBYING ACTIVITY.** Select as many codes as necessary to reflect the general issue areas in which the engaged in lobbying on behalf of the client during the reporting period. Using a separate page for each code information as requested. Attach additional page(s) as needed.

15. General issue area code MMM - Medicare/Medicaid (one per page)

16. Specific lobbying issues

Implementation of Section 641 of Public Law 108-173, Medicare Prescription Drug, Improvement, and Modernization Act of 2003 - relating to demonstration project for self-injectable drugs.

S.239, Medicare Enhancements for Needed Drugs Act of 2005 - relating to non-interference.

S.635, H.R.1298, Kidney Care Quality and Improvement Act of 2005.

17. House(s) of Congress and Federal agencies contacted  Check if None

Centers for Medicare and Medicaid Services  
Department of Health & Human Services  
House of Representatives  
Senate

18. Name of each individual who acted as a lobbyist in this issue area

Name			Covered Official Position (if applicable)
Rosemary T.	Haas	Mr.	
Elaine R.	Leavenworth	Ms.	
Jennifer M.	Luray	Ms.	
Cynthia B.	Sensibaugh	Ms.	
John M.	Taylor	Mr.	Associate Commissioner, FDA
James J.	White	Mr.	
Adele R.	Witenstein	Ms.	

19. Interest of each foreign entity in the specific issues listed on line 16 above  Check if None

0000142406



Printed Name and Title Timothy M. Shannon - Director, Government Affairs Operations

LD-2DS (Rev. 4.06)

Page 18



Go to

Registrant Name Abbott Laboratories Client Name Abbott Laboratories

**ADDENDUM for General Lobbying Issue Area MMM**

16. Specific lobbying issues (continued from previous page)

Implementation of Section 302 of Public Law 108-173, Medicare Prescription Drug, Improvement, and Modernization Act of 2003 - relating to durable medical equipment.

0000142407



LD-2DS

Add page to continue specific issues description for this

Page 9

Registrant Name Abbott Laboratories

Client Name Abbott Laboratories

**LOBBYING ACTIVITY.** Select as many codes as necessary to reflect the general issue areas in which the engaged in lobbying on behalf of the client during the reporting period. Using a separate page for each code information as requested. Attach additional page(s) as needed.

15. General issue area code TRD - Trade (Domestic & Foreign) (one per page)

16. Specific lobbying issues

S.1307, H.R.3045, Dominican Republic-Central America-United States Free Trade Agreement Implementation Act - relating to intellectual property.

International intellectual property protection.

World Health Organization Initiatives regarding pediatric nutrition.

17. House(s) of Congress and Federal agencies contacted  Check if None

Department of Agriculture

Office of U.S. Trade Representative

Department of Commerce

House of Representatives

Department of Health & Human Services

Senate

Department of State

Department of the Treasury

Executive Office of the President

18. Name of each individual who acted as a lobbyist in this issue area

Name			Covered Official Position (if applicable)
P. Claude	Burcky	Mr.	
Rosemary T.	Haas	Ms.	
Elaine R.	Leavenworth	Ms.	
Jennifer M.	Luray	Ms.	
Howard D.	Scholck	Mr.	
Cynthia B.	Sensibaugh	Ms.	
John M.	Taylor	Mr.	Associate Commissioner, FDA
James J.	White	Mr.	
Adele R.	Witenstein	Ms.	

19. Interest of each foreign entity in the specific issues listed on line 16 above  Check if None

1000142408



Go to

Registrant Name Abbott Laboratories Client Name Abbott Laboratories

**ADDENDUM for General Lobbying Issue Area TRD**

16. Specific lobbying issues (continued from previous page)

International pharmaceutical market access.  
International medical device reimbursement policy.  
HIV/AIDS procurement policy.

0000142409



LD-2DS

---

*Add page to continue specific issues description for this*

Page 1

↓

Registrant Name Abbott Laboratories Client Name Abbott Laboratories

**LOBBYING ACTIVITY.** Select as many codes as necessary to reflect the general issue areas in which th engaged in lobbying on behalf of the client during the reporting period. Using a separate page for each co information as requested. Attach additional page(s) as needed.

15. General issue area code CPT - Copyright/Patent/Trademark (one per page)

16. Specific lobbying issues

H.R.2795, Patent Act of 2005 - relating to patent reform.

17. House(s) of Congress and Federal agencies contacted  Check if None

House of Representatives  
Senate

18. Name of each individual who acted as a lobbyist in this issue area

Name			Covered Official Position (if applicable)
Elaine R.	Leavenworth	Ms.	
John M.	Taylor	Mr.	Associate Commissioner, FDA
James J.	White	Mr.	

19. Interest of each foreign entity in the specific issues listed on line 16 above  Check if None

3000142410



Printed Name and Title Timothy M. Shannon - Director, Government Affairs Operations

LD-2DS (Rev. 4.06)

Page 1